Listen to the article
Study Reveals Heart Health Benefits of GLP-1 Medications Vanish After Discontinuation
People who discontinue popular weight-loss and diabetes medications may rapidly lose the cardiovascular benefits these drugs provide, according to new research from Washington University School of Medicine in St. Louis.
GLP-1 receptor agonists—including semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound)—have been shown to reduce the risk of heart attack and stroke in addition to their weight management benefits. However, the new study reveals that these protective effects quickly diminish once patients stop taking the medication.
“Many people are excited to start GLP-1s, but many stop within a few months,” explained Ziad Al-Aly, senior clinical epidemiologist at Washington University Medicine. “Some research looked at weight regain after people stop—we wanted to know what happens to heart health when people stop.”
The observational study, published in BMJ Medicine, followed more than 333,000 U.S. veterans with type 2 diabetes for approximately three years. Researchers compared cardiovascular outcomes between those taking GLP-1s and those taking sulfonylureas, an older class of oral diabetes medications.
Patients who used GLP-1s continuously for three years experienced an 18% reduction in cardiovascular risk. However, this protection eroded rapidly after discontinuation. Those who stopped taking the medication for just six months saw their risk increase by 4%. After one year without the medication, the risk rose by 14%, and by the two-year mark, the risk was 22% higher.
“We expected some loss of benefit after stopping, but the pace was striking,” Al-Aly noted. “Protection that takes years to accumulate can vanish in a few months of stopping.”
When patients resumed taking GLP-1s after a break, they regained some cardiovascular protection, but not at the level they would have achieved with continuous use. Restarting the medication provided only a 12% risk reduction compared to the 18% seen in those who never interrupted treatment.
The study findings highlight that GLP-1 medications do more than just promote weight loss. They also reduce cholesterol, blood pressure, inflammation, and insulin resistance—all factors that affect heart health. When patients stop the medication, these markers begin trending in a negative direction.
Dr. Bradley Serwer, an interventional cardiologist and chief medical officer at VitalSolution, described this as consistent with what’s known about chronic disease management.
“When treating patients with chronic diseases, the primary objective is long-term success,” said Serwer, who was not involved in the study. “When a crucial component of the therapeutic plan, such as medications like GLP-1, is discontinued, the disease process tends to resume at a rapid pace.”
The researchers characterized this rebound effect as “metabolic whiplash,” noting that unlike weight regain, these metabolic changes occur silently.
“It doesn’t announce itself until it surfaces in the ER as a heart attack or a stroke,” Al-Aly warned.
The study does have limitations. As an observational study, it could only establish association rather than causation. Additionally, the patient population consisted mainly of older male veterans, potentially limiting the applicability to broader demographics. The researchers noted they used “target trial emulation” techniques to apply the logic of randomized trials to real-world data and adjusted for clinical conditions as they changed over time.
Serwer pointed out another consideration: “The patients in this study were at a higher risk of developing coronary artery disease. Many individuals taking GLP-1 medications do so for weight loss, and may not necessarily have significant cardiovascular risk factors, such as diabetes, hypertension or hyperlipidemia.”
The findings suggest GLP-1 medications should be viewed as long-term treatments rather than temporary interventions. For those considering these medications, experts recommend a comprehensive approach.
“While GLP-1s are designed to enhance metabolic health, they should be combined with healthy behaviors to help ensure long-term benefits,” Serwer advised. “It is crucial to adopt a holistic approach that emphasizes lifestyle modifications, diet and exercise.”
The research adds important context to the ongoing discussion about GLP-1 medications as their popularity continues to rise for both diabetes management and weight loss. For patients and healthcare providers, it underscores the importance of treatment continuity and comprehensive care planning when using these medications.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
8 Comments
This study raises important questions about the long-term management of type 2 diabetes and the use of GLP-1 drugs. While they offer benefits, the potential for rapid reversal of those benefits is troubling. More research is needed to fully understand the implications.
Agreed, the findings emphasize the complex and nuanced nature of treating chronic conditions like type 2 diabetes. Careful monitoring and a personalized approach are critical when it comes to medications like GLP-1 drugs.
The study’s findings are a good reminder that the benefits of medications can be highly dependent on consistent use. While GLP-1 drugs like Ozempic offer cardiovascular and weight management advantages, the rapid loss of those benefits after stopping is an important consideration for patients and doctors.
Absolutely, the reversibility of the benefits is a crucial factor to weigh when deciding whether to start or stop these types of medications. Careful monitoring and a collaborative approach between patient and provider is essential.
This research highlights the complexities involved in managing type 2 diabetes and the use of GLP-1 medications. While these drugs can provide important benefits, the study’s findings suggest that maintaining those benefits requires long-term, consistent use. More work is needed to fully understand the implications.
Interesting research on the cardiovascular benefits of GLP-1 drugs like Ozempic. It’s concerning to hear that these benefits can disappear quickly after discontinuing the medication. This highlights the importance of understanding the long-term effects of these drugs.
You’re right, the rapid loss of cardiovascular protection is an important finding. It underscores the need for patients to work closely with their doctors when considering stopping these medications.
It’s concerning to see that the cardiovascular benefits of GLP-1 medications can disappear so quickly after discontinuation. This underscores the importance of long-term management and the need for patients to work closely with their healthcare providers when considering stopping these treatments.